Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells
NCT00892866 · View on ClinicalTrials.gov ↗
Study Summary
This research trial studies carbonic anhydrase 9 (CA-IX), p16, proliferative markers, and human papilloma virus (HPV) in diagnosing cervical lesions in patients with abnormal cervical cells. Studying biomarkers in abnormal cervical cells may improve the ability to find cervical lesions and plan effective treatment.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Cytology Specimen Collection Procedure
Study Locations (20)
Idaho
- Saint Alphonsus Cancer Care Center-Boise — Boise
- Saint Alphonsus Cancer Care Center-Caldwell — Caldwell
- Kootenai Health - Coeur d'Alene — Coeur d'Alene
- Walter Knox Memorial Hospital — Emmett
- Idaho Urologic Institute-Meridian — Meridian
- Saint Alphonsus Medical Center-Nampa — Nampa
- Kootenai Clinic Cancer Services - Post Falls — Post Falls
- Kootenai Cancer Clinic — Sandpoint
California
- UC San Diego Moores Cancer Center — La Jolla
- Kaiser Permanente Los Angeles Medical Center — Los Angeles
- UCLA / Jonsson Comprehensive Cancer Center — Los Angeles
- Saint Joseph Hospital - Orange — Orange
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange
- Olive View-University of California Los Angeles Medical Center — Sylmar
Arizona
- Banner University Medical Center - Tucson — Tucson
- University of Arizona Cancer Center-North Campus — Tucson
Connecticut
- Hartford Hospital — Hartford
- The Hospital of Central Connecticut — New Britain
Illinois
- NorthShore University HealthSystem-Evanston Hospital — Evanston
- Good Samaritan Regional Health Center — Mount Vernon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 877 participants |
| Start Date | 2009-04-13 |
| Est. Completion | 2025-05-31 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00892866
The ClinicalTrials.gov registry entry for NCT00892866 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 877 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GOG Foundation, which has 37 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Human Papillomavirus Infection appearing as the primary indexed condition, and to 2 interventions — of which Laboratory Biomarker Analysis is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00892866 reports 20 study locations spanning 5 distinct geographic areas — top geographies include Idaho, California, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00892866 about?
NCT00892866 is a clinical study titled "CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells". This research trial studies carbonic anhydrase 9 (CA-IX), p16, proliferative markers, and human papilloma virus (HPV) in diagnosing cervical lesions in patients with abnormal cervical cells. Studying biomarkers in abnormal cervical cells may improve the ability to find cervical lesions and plan effe...
What is the current status of trial NCT00892866?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 877 participants. The study started on 2009-04-13. Estimated completion is 2025-05-31.
What conditions does trial NCT00892866 study?
This clinical trial studies the following conditions: Human Papillomavirus Infection, Atypical Endometrial Hyperplasia, Stage 0 Cervical Cancer AJCC v7. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00892866?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cytology Specimen Collection Procedure (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00892866?
This trial is sponsored by GOG Foundation, which has 37 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00892866 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.